Request Deal Involvement

T. Rowe Price led a $518m Series B financing round in Eikon Therapeutics.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Bioscribe

pr advisors

Bioscribe

or

Principals

HAREL GROUP

bidder

HAREL GROUP

ABU DHABI INVESTMENT AUTHORITY (ADIA)

bidder

ABU DHABI INVESTMENT AUTHORITY (ADIA)

SOROS FUND MANAGEMENT LLC

bidder

SOROS FUND MANAGEMENT LLC

HARTFORD HEALTHCARE ENDOWMENT

bidder

HARTFORD HEALTHCARE ENDOWMENT

CANADA PENSION PLAN INVESTMENT BOARD (CPP INVESTMENTS)

bidder

CANADA PENSION PLAN INVESTMENT BOARD (CPP INVESTMENTS)

UC INVESTMENTS

bidder

UC INVESTMENTS

FORESITE CAPITAL MANAGEMENT LLC

bidder

FORESITE CAPITAL MANAGEMENT LLC

T. ROWE PRICE GROUP INC

bidder

T. ROWE PRICE GROUP INC

ECOR1 CAPITAL

bidder

ECOR1 CAPITAL

LUX CAPITAL MANAGEMENT

bidder

LUX CAPITAL MANAGEMENT

INNOVATION ENDEAVORS

bidder

INNOVATION ENDEAVORS

EIKON THERAPEUTICS INC

target

EIKON THERAPEUTICS INC

SCHRODERS CAPITAL REAL ESTATE

bidder

SCHRODERS CAPITAL REAL ESTATE

AME CLOUD VENTURES

bidder

AME CLOUD VENTURES

STEPSTONE GROUP

bidder

STEPSTONE GROUP

GENERAL CATALYST PARTNERS

bidder

GENERAL CATALYST PARTNERS

E15 VC

bidder

E15 VC

THE COLUMN GROUP

bidder

THE COLUMN GROUP

HORIZONS VENTURES LTD

bidder

HORIZONS VENTURES LTD

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - T. Rowe Price led a $518m Series B financing round in Eikon Therapeutics.